News Medical on MSN
The mechanisms behind thrombocytopenia in patients with portal hypertension and chronic liver disease
Persistent liver injury halts the regenerative capacity of hepatocytes and activates mechanisms that result in the ...
MedPage Today on MSN
FDA Probes Child Death Linked to Drug for Blood Clotting Disorder
The FDA said it has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in patients ...
The U.S. Food and Drug Administration said on Friday it is investigating the death of a child who developed harmful ...
The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...
The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...
News-Medical.Net on MSN
EULAR develops new disease activity score for antiphospholipid syndrome
EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies ...
NANJING -- A Chinese research team has developed a combination of nanobodies that shows potent and broad efficacy against ...
Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, ...
The European Alliance of Associations for Rheumatology – has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS). It ...
Long-term follow-up of the international, multicenter phase 2 trial SAKK 01/10 found that single-dose carboplatin and involved-node radiotherapy (INRT) yielded an exceptional long-term performance ...
US FDA grants fast track designation to BTK inhibitor, rilzabrutinib to treat immune thrombocytopenia: Paris Thursday, November 19, 2020, 09:00 Hrs [IST] The US Food and Drug Admi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback